The tissue specificity of an inherited predisposition to cancer has been known of and speculated upon for a long time ([@bib25]; [@bib22]). It is a pattern seen in both tumour suppressor genes (TSGs) and proto-oncogenes (POGs). For example, inherited mutations in the TSG *BRCA1* severely increase the risk of cancer in breast and ovarian tissues, but cause no added risk of cancer in many other tissue types ([@bib44]). Similarly, inherited mutations in the *KIT* POG specifically increase the risk of gastrointestinal stromal tumours ([@bib21]).

Attempts to explain these phenomena have largely focussed on TSGs ([@bib3]), with the usual assumption being that a given TSG acts as a critical cancer suppressor in the predisposed tissues, but not in those tissues with no elevated risk of hereditary cancer ([@bib41]; [@bib15]). For example, [@bib41]; [@bib15]) proposed that *RB1* had been recruited by evolutionary processes for the regulation of cell division in retinal and bone tissues, given that *RB1* germline mutations were associated with high lifetime risks of retinoblastoma ([@bib18]) and osteosarcoma ([@bib37]).

This explanation of tissue specificity was formalised into an evolutionary model of cancer suppression by [@bib27]. The model is based on multistage carcinogenesis and quantifies how cancer risk increases with a larger body size (more cells) and a longer lifespan (more cell divisions) (a relationship strongly supported by data from humans and dogs; [@bib28]), and how increased pre-reproductive risk drives natural selection for tissue-specific increases in cancer suppression. This recognition that cancer suppression is an evolving trait resolves the paradox first noted by [@bib29]: why don\'t large long-lived humans have much higher rates of cancer than small short-lived mice? This suppression is predicted to involve either tissue-specific mechanisms that directly reduce the risk of the target cancer (e.g., a TSG upregulated in a single tissue) or more general mechanisms affecting all tissues that would also lower the risk of all cancers. Examples of general mechanisms (global telomerase suppression, and early contact inhibition) have already been identified in large and long-lived rodents ([@bib33], [@bib34]). Tissue-specific mechanisms are harder to detect, but the serendipitous availability of tissue-specific mutations would predict that different TSGs may be recruited independently over time in different tissues within a species, and that different TSGs may be recruited in the same tissue in different species clades.

One potential consequence of this evolutionary process would be that TSGs are only expressed in tissues where they actively suppress carcinogenesis. However, most TSGs and POGs are expressed in every type of normal human tissue. This was first investigated using *RB1* that was found to be expressed in every tissue tested ([@bib10]; [@bib11]; [@bib20]). Studies of other genes have found the same pattern in gene expression ([@bib8]; [@bib40]) and protein data ([@bib30]).

The ubiquitous expression of TSGs and POGs has thus been recognised as an enigma of cancer research ([@bib17]; [@bib42], [@bib43]; [@bib7]; [@bib4]; [@bib8]; [@bib3]; [@bib40]), prompting alternative explanations that do not predict differences in expression across tissue types (see [@bib3]; [@bib9]). For example, it has been proposed that the specificity of *BRCA1* to breast and ovarian cancers might result from *BRCA1* mutations being less likely to induce apoptosis in breast and ovarian tissues than in other tissues ([@bib6], see also [@bib24]). However, such *ad hoc* hypotheses lack generality because they fail to explain why such tissue specificity is the rule rather than the exception.

Recent work on TSGs suggests that their level of expression, rather than presence or absence, may be an important indicator of the cancer suppressing activity. The TSGs have multiple functions affecting tissues generally, in addition to their roles in cancer suppression ([@bib39]; [@bib36]); however, a higher tissue-specific level of expression may indicate a role in suppressing cancer in the target tissue. [@bib2] recently argued that higher levels of TSG expression correspond to lower cancer risk. For example, mice with slightly reduced expression levels (80%) of the TSG *Pten* have intermediate mammary tumour incidence compared with *Pten*+/+ (100%) and *Pten*+/− (50%) mice ([@bib1]). In humans, haploinsufficiency of the TSGs *PTEN* ([@bib23]) and *TP53* ([@bib38]) has been linked to cancer, and this runs counter to the expectation that a single copy of a TSG is sufficient to suppress cancer. In such cases, loss-of-heterozygosity events of the remaining wild-type allele were not found. This suggests that, at least in some cases, a 50% reduction in expression substantially reduces the protective effect of a TSG.

Overall, these findings suggest that TSGs may be expressed at constitutively higher levels in the tissues where they are recruited to suppress cancer relative to those in which they are not. This hypothesis has been tested by two studies to date; however, support was weak or absent. [@bib30] examined the protein expression levels of the DNA mismatch repair tumour suppressors, MLH1 and MSH2, commonly associated with colorectal and uterine cancers. They found that both proteins had significantly higher expression in the susceptible tissues, but only if nonsusceptible testes tissue that showed the highest expression level for both proteins was excluded. [@bib19] used microarray data from noncancerous samples of 73 tissues to examine the relative expression of 51 genes linked to hereditary cancer and did not find the predicted pattern in POGs or TSGs.

The two-hit role of TSGs in cancer suppression is well established; however, it is also possible for POGs to be recruited to provide one-hit protection ([@bib27]). The role of POGs in transmitting growth signals ([@bib5]) appears to make them less likely candidates for cancer suppression, as it requires that each added POG defines a new necessary signal for tissue growth. However, POGs are implicated in some familial cancers (the first was *RET*; [@bib26]) and their possible role in the evolution of cancer suppression needs to be investigated. To this end, we were interested in testing the same hypothesis in POGs that has been proposed for TSGs: that a POG has higher expression in the susceptible tissue type(s) assuming that a susceptible tissue is where the POG provides a required signal for tissue growth.

The goal of this study was to test the prediction that TSGs and POGs implicated in familial cancer in a specific tissue are expected to have a high level of expression in that tissue. Using 15 TSGs and 8 POGs implicated in various tissue-specific familial cancers, we tested for higher expression in the affected tissue across 12 tissue types (plus some additional subtypes) using published mRNA expression data from normal (noncancerous) tissues.

Materials and Methods
=====================

Gene expression data set
------------------------

We used data from 35 independently published microarray data sets documenting gene expression for a range of human tissues (see [Table 1](#tbl1){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}) using the HG-U133A Affymetrix (Santa Clara, CA, USA) platform. These data were compiled and normalised by [@bib45], and the data set is publicly available online at ArrayExpress (Accession no. E-MATB-27). The multistudy data set was downloaded using the Bioconductor software ([@bib13]) in R ([@bib31]). All probe sets were retained in our subset. Most cancer-related genes were covered by a single probe set. In those cases where two probe sets were present (*RB1* and *PTCH1*), these were included as replicate measures of expression.

In our analysis we used all of the broad tissue categories used to group the biological samples in the data set except for cell line and liver, because cell line samples may not accurately reflect expression at the tissue level *in vivo*, and the liver tissue category contained only a single sample. We also removed tissues annotated as 'disease\' or 'neoplasia\' as only normal tissue was being analysed. The final 12 tissue categories used in the analysis and their corresponding sample sizes are represented in [Table 1](#tbl1){ref-type="table"}.

Criteria for selecting genes
----------------------------

Our initial screen required that a TSG or POG could be included in the analysis only if it was implicated in cancer via both germline and somatic mutations (using [Supplementary Table S1](#sup1){ref-type="supplementary-material"} in [@bib12]). Both types of mutational effect were included in the screen in order to select only those TSGs and POGs likely to increase susceptibility across a range of developmental conditions in which the genes are mutated. For example, if a gene had a germline effect, but no known somatic effect, then this could indicate that the oncogenic activity of the mutant gene was restricted to very early development, a possibility our analysis of adult tissue could not detect.

In our second screen, we identified tissues significantly at risk from germline mutation using the criterion that lifetime cancer risk (by age 70 years) for individuals carrying a mutation in the target gene had to be ≥25% using median values from [@bib21]. When relative risk (RR) scores were reported, the RR was converted using baseline risk data (*x*) from Surveillance Epidemiology and End Results (SEER) ([@bib32]), that is, (*x)(*RR) ≥25. For some genes, the 25% criterion excluded all tissue types. For these genes alone, a single tissue type that most exceeded a lower threshold of 15% lifetime risk was retained.

In applying this second screen it was found that of the POGs identified in the first screen, only *RET* (multiple endocrine neoplasia type II), *HRAS*, and *KIT* were included in [@bib21]. *RET* passed the second screen. However, as the absence of the other POGs was probably because of their relatively recent discovery as hereditary cancer genes, we used other sources to assess risk. Each one of these genes was associated with only one major cancer type, as reported in the Cancer Gene Census ([@bib12]; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}), and all of these cancer types were found to be above the 25% lifetime risk threshold using data from OMIM (Online Mendelian Inheritance in Man; see [@bib14]).

Cancers affecting a tissue not represented in the 12 tissue types were not considered (e.g., colorectal cancer). Also excluded were (1) cancer types with diverse tissues of origin such as harmartomas and desmoid tumours, and (2) cancer types with unknown tissues of origin, such as rhabdoid tumours.

Statistical tests
-----------------

All statistical tests were performed in the statistical program R ([@bib31]), with the exception of the nested ANOVA model for which Minitab 16 (Minitab Inc., Pennsylvania, PA, USA) was used. The normality and equal variance assumptions of the log~2~(expression) data for each gene were tested using the Jarque--Bera test and the Bartlett test. As the data for several genes were found to be nonnormal, in most cases nonparametric statistical tests were performed.

Tissue and subtissue categories
-------------------------------

All statistical testing for higher expression in susceptible tissues relative to nonsusceptible tissues were performed initially using the 12 broad tissue categories with (usually) one tissue identified as 'susceptible\' for each gene and the remainder grouped as 'nonsusceptible\'. For some genes it was possible to use subtissue data (given an adequate sample size \>2; see [Table 1](#tbl1){ref-type="table"}) to refine the initial analysis by identifying the susceptible subtissue within the susceptible tissue using OMIM ([@bib14]), so that the remaining subtissue samples of that tissue type could be grouped as 'nonsusceptible subtissues\', creating a 13th category.

Comparing gene expression in susceptible *vs* nonsusceptible tissue groups
--------------------------------------------------------------------------

The grand mean expression values of each gene in its susceptible *vs* nonsusceptible tissues/subtissues were compared using the one-tailed Wilcoxon signed rank test applied separately to TSGs and POGs. The one-tailed test was performed, given the directional alternate hypothesis of higher expression in susceptible tissue. For each gene, the grand means were calculated as the unweighted average of the means of the relevant tissue/subtissue groups.

In a second analysis, each gene was tested individually. First, for each gene, we tested for significant differences in expression levels among the tissue/subtissue groups using the Kruskal--Wallis test. If significant expression-level differences between tissues were established (*P*\<0.05 after Bonferroni correction for testing multiple genes), the Kruskal--Wallis multiple comparison test was performed across the tissue types. In this *a posteriori* test, which controlled the family-wise error rate at 0.05, the tissue means were ranked and grouped by significance, with the 'A\' group corresponding to the highest expression level. Tissues could be assigned to more than one group, for example, expression in a tissue classified as 'AB\' would only be significantly higher than tissues not in groups 'A\' or 'B\'. Only those tissue types marked as 'A\' alone (i.e., not 'AB\' etc.) were considered most highly expressed (see [Figure 1](#fig1){ref-type="fig"}).

The number of 'A\' classifications assigned to the susceptible tissue/subtissue of TSGs or POGs relative to the total number of 'A\' classifications was used to determine whether there was a nonrandom association. The statistical significance of the relationship was determined by simulated resampling of the data to determine the distribution of the number of 'A\'s expected to be assigned to the susceptible group under the null hypothesis. A total of 10 000 trials were run and each trial involved cycling through each of the TSGs (or POGs) in turn and taking a random sample of size 1 or 2 (corresponding to the number of susceptible tissues for that gene) from the observed distribution of letter groupings for that gene. The number of 'A\'s chosen across all TSGs (or POGs) was the score for that trial. The statistical significance of the observed score was evaluated based on its position relative to the null distribution.

Tests of lab effect
-------------------

We examined the effect of using data from different laboratories, as these effects are known to be strong ([@bib46]). Most labs tested only one tissue type, and hence to avoid subtissue variation we only compared labs that used the same subtissue type to represent that tissue. The resulting data set was analysed using a nested ANOVA model (Model: Expression=Subtissue+Gene+Lab(Subtissue)+Gene × Subtissue+Gene × Lab(Subtissue)), with Gene and Subtissue as fixed effects, and Lab as a random effect. Of interest is the Gene × Lab(Subtissue) interaction where the null expectation is that the ordering of expression across genes is constant for a given subtissue. We also calculated the (Pearson) correlation for gene expression levels both within and between labs. Within labs the multiple correlation coefficients were averaged using the Fisher\'s *z*-transform (*z*=(1/2)ln\[(1+*r*)/(1−*r*)\]), and between labs the correlation was based on the average expression levels of each lab.

Results
=======

We identified 36 genes that had both hereditary and somatic mutations linked to cancer, of which 28 were represented by the probe sets within the expression array. Of these 36 genes, 23 (15 TSGs and 8 POGs) satisfied our criteria for a high-risk familial effect, with each affecting a single susceptible tissue, with the exception of *PRKAR1A*, a TSG that defined two susceptible tissues ([Table 2](#tbl2){ref-type="table"}). Within this group, it was possible to identify susceptible *vs* nonsusceptible subtissues within the susceptible tissue category in 11 TSGs and 2 POGs ([Table 2](#tbl2){ref-type="table"}).

Analysis of the average expression of the 15 TSGs and 8 POGs showed that both groups had significantly higher expression in susceptible tissue categories, where mutations result in familial cancer, relative to nonsusceptible tissue categories. The mean log~2~ expression levels (±1 s.e.) of TSGs in susceptible and nonsusceptible tissue were 0.368±0.254 and −0.130±0.082, respectively, and in POGs they were 2.24±1.06 and 0.225±0.209, respectively ([Table 2](#tbl2){ref-type="table"}) (Wilcoxon signed rank test: TSGs, *V*=89, *P*=0.05, d.f.=14; POGs, *V*=35, *P*=0.008, d.f.=7). This reflected the finding that 10 of 15 TSGs and 7 of 8 POGs had a higher expression level in the susceptible tissue categories relative to the mean of the nonsusceptible tissue categories ([Table 2](#tbl2){ref-type="table"}). The same trend was also found when the susceptible tissue was more narrowly defined as a subtissue (Wilcoxon signed rank test: TSGs, *V*=91, *P*=0.04, d.f.=14; POGs, *V*=33, *P*=0.02, d.f.=7), again with 10 of 15 TSGs and 7 of 8 POGs having a higher expression level in the susceptible subtissue relative to the mean of the nonsusceptible tissues ([Table 2](#tbl2){ref-type="table"}).

We next examined the more stringent hypothesis that in its susceptible tissue or subtissue the expression level of a TSG or POG is in the statistically most highly expressed tissue (or group of tissues) for that gene. We first established that there was highly significant differences in expression among tissues for all 23 genes (Kruskal--Wallis test; *P*\<0.01 in all cases, after Bonferroni correction; see [Table 2](#tbl2){ref-type="table"}). *A posteriori* testing to assign a significance category to each susceptible tissue showed that 33% (5 out of 15) of TSGs and 63% (5 out of 8) of POGs were most highly expressed in their susceptible tissue ([Table 2](#tbl2){ref-type="table"}). Data resampling tests identified these patterns to be significant for both TSGs (*P*=0.02) and POGs (*P*=0.0003). The pattern for TSGs became much stronger when we refined the analysis using, where possible, expression data from susceptible subtissue rather than from the broad tissue category. Of the 11 TSGs where a susceptible subtissue was identified, 4 out of the 8 that were not characterised by significance category 'A\' in the initial tissue-level analysis moved into significance category 'A\' in the subtissue analysis. The 3 TSGs significant at the tissue category level remained so in the subtissue analysis ([Table 2](#tbl2){ref-type="table"}), so that 9 out of 15 TSGs (60% *P*=0.0001) had their significantly highest expression in their susceptible tissue ([Figure 2A](#fig2){ref-type="fig"}). There was no difference in the number of 'A\'s between the subtissue and the broad tissue category score for POGs ([Table 2](#tbl2){ref-type="table"}), and hence their significance was unchanged (*P*=0.0003). The overall pattern in POGs is shown in [Figure 2B](#fig2){ref-type="fig"}.

We examined whether using data from different laboratories added significant variation within our tissue groupings using the cases where it was possible to test for heterogeneity in the ranking of the expression values of all genes within the same subtissue. There were six types of subtissue that were used in more than one lab, with two or three labs per subtissue ([Table 3](#tbl3){ref-type="table"}). With lab nested within subtissue, ANOVA revealed a highly significant Gene by Lab (Subtissue) interaction (*P*\<0.001; [Table 3](#tbl3){ref-type="table"}), indicating that, for at least some genes, the ranking of the expression levels across subtissues varied among labs. This laboratory effect would lessen the chance of the data revealing a consistent pattern.

Despite this heterogeneity, the correlation in gene expression across labs was generally quite high. Of the 10 possible pairwise correlations, 5 explained \>50% of the variance in the ranking (i.e. *r*^2^\>0.5), whereas 4 explained \<33% variance ([Table 3](#tbl3){ref-type="table"}).

Another potential source of variation is between replicate samples within labs. Using the same set of labs, the correlation in the gene expression values within labs was the same, averaging 0.705 (*vs* 0.704 between labs; [Table 3](#tbl3){ref-type="table"}), with all values explaining \>33% of the variance (and 5 out of 9 explaining \>50% of the variance). However, it is clear that the consistency of replication within labs is relatively poor.

Discussion
==========

We examined the expression levels of 15 TSGs and 8 POGs implicated in a high risk of familial cancer and found that a gene\'s highest expression was typically found in the tissue susceptible to the cancer with which it was associated. Specifically, the overall expression level was generally higher in susceptible tissue (or subtissue) compared with the average of nonsusceptible tissue for both TSGs (10 out of 15 TSGs, *P*\<0.05) and POGs (7 out of 8 POGs, *P*\<0.05) and, more importantly, that gene expression in the susceptible tissue (or subtissue) was within the highest expression group observed in 9 out of 15 TSGs (*P*\<0.001) and in 5 out of 8 POGs (*P*\<0.001). Despite the high level of variability in the data (see below), 3 TSGs and 3 POGs showed a level of expression significantly higher in their susceptible tissue (or subtissue) than in all 11 (or 12) other types (see [Table 2](#tbl2){ref-type="table"}). The remainder showed high expression in their susceptible tissue (or subtissue) that could not be statistically distinguished from levels in some other tissues; however, our statistical testing (via data resampling) incorporated this ambiguity in establishing the highly significant relationship between high expression and the susceptible tissue.

This relationship was predicted by the hypothesis of Weinberg ([@bib41]; [@bib15]) that TSGs have been evolutionarily recruited in the susceptible tissues to suppress cancer and that this has occurred via upregulation of the expression of different genes in different tissues. This is a basic assumption of the model of [@bib27] for the evolution of cancer suppression: if a given cancer results in a significant loss of fitness, then natural selection will act on any genetic variation for tissue-specific expression of TSGs and POGs that results in a decrease in the occurrence of that cancer during the pre-reproductive and reproductive period.

Proto-oncogenes were found to show the same pattern as TSGs. This result could be due to POGs being recruited as additional cancer suppressors in a manner analogous to TSGs. This would require that each added POG adds one more necessary tissue-specific signalling pathway and hence one more 'hit\' in the progression of multistage carcinogenesis. An alternative possibility is that POGs generally have constitutively higher expression in the tissues in which they have a critical role in tissue development and maintenance ([@bib35]). If so, hereditary cancers arising from mutations in a specific POG occur because the tissue is especially sensitive to growth signals sent by that POG, or because such mutations have a bigger effect of perturbing some other potentially oncogenic cell function than mutations in a POG that is expressed at lower levels. The link between high expression and an important role in cell signalling is appealing, and may be a very general pattern; however understanding the potential role of POGs in the evolution of cancer suppression requires a comparative approach to determine whether larger, longer-lived organisms tend to have additional layers of highly expressed POGs associated with a given tissue.

A previous study ([@bib19]) failed to find a consistent relationship between the expression of TSGs and POGs in susceptible relative to nonsusceptible tissues. They did find a trend towards overexpression of POGs in susceptible tissues consistent with our results; however, they also found a trend for the underexpression of TSGs in susceptible tissues. This difference is likely because of differences in methodology. For each gene--disease combination, the authors ranked the tissues by their degree of susceptibility based upon the number of times a tissue was co-mentioned in the PubMed literature with a disease of the given gene. The most highly mentioned 25 tissues were considered as the susceptible tissues for the given disease--gene combination in their statistical test. The use of 25 susceptible tissues for a given disease--gene combination is expected to mask the pattern that we were looking for: the evolutionary recruitment of cancer suppression in a very tissue-specific manner.

Our finding that the highest level of expression of a TSG or a POG generally occurs in the tissue susceptible to the oncogenic effects of that gene was highly statistically significant, but it was only established for 14 of the 23 genes examined. However, it is likely that our results are conservative given a range of biological and experimental factors that could act to mask the relationship between gene expression and cancer suppression activity. A number of experimental factors can cause unpredictable variation in the measures of gene expression. One important source of variation in expression that our study has highlighted is the precise nature of the tissue samples. The results of subtissue tests showed that in eight tests on TSGs where the susceptible tissue was not in the most highly expressed group, the outcome was reversed for four of the TSGs when the susceptible subtissue was used ([Table 2](#tbl2){ref-type="table"}). This result shows that reliable results can only be obtained when the specific cell type(s) that are susceptible to the cancer are examined.

Other important sources of experimental variation acting to mask general patterns were between-sample (within-lab) variation and between-lab variation. Within labs using the same subtissue, the average correlation in the expression of the 23 genes was *r*=0.705. This leaves 50% of the variance unexplained because of between-sample effects. When all within-lab expression values were averaged to minimise the between-sample variance and these averages were compared between labs, the correlation was not improved (*r*=0.704), highlighting substantial between-lab variation. This high level of between-lab variation (*vs* within-lab, between sample variation) was substantiated using ANOVA that revealed a highly significant lab(subtissue) × gene interaction (*P*\<0.001; see [Table 3](#tbl3){ref-type="table"}). The same Affymetrix array was used by all labs and hence this was not the source of the variation. Many factors could contribute to both the between-sample and between-lab variation including the nature and physiological state of the patients sampled (gender, age, ethnicity, general health).

It may be possible to control for many of these factors in future studies by standardising tissue collection protocols, and by using either protein levels directly or higher quality gene expression data such as RNAseq. However, other biological factors may still act to mask the association between expression and tissue susceptibility. For example, some of these genes may only act as critical cancer suppressors, and thus be highly expressed, during certain periods of development. This possibility has been proposed (but not supported) in the relationship between the *RB1* gene and retinoblastoma ([@bib20]). In our study, two DNA-repair TSGs, *MSH2* and *BRCA1*, both of which predispose to ovarian cancer, were found to have low expression in the ovaries, but extremely high expression in testes tissue. As ovarian tissues stop dividing before adulthood, but adult testes tissues continue to proliferate, the expression of these genes in ovarian tissues may be highest during early development. The small sample size of pre-adult tissues in our data set precluded the testing of this hypothesis. It would be useful to include tissue from different developmental stages (e.g., infant, child, adult) in future analyses. Alternatively, the failure to find elevated expression in the ovaries may be because of choosing an inappropriate susceptible tissue, as many high-grade serous ovarian tumours have been found to originate in the fallopian tube ([@bib16]).

In conclusion, our findings support the hypothesis that a high level of expression is a marker of oncogenic importance in both TSGs and POGs, as predicted under the model of [@bib27] for the evolution of cancer suppression. This approach has potential clinical applications. First, cancer-related genes showing unusually high expression in normal tissue can be examined further for a possible role in the sporadic cancers of that tissue. Second, the finding of high expression of a known TSG or POG in a particular cell type is a potentially useful tool for identifying candidate genes in our search for causes of familial cancers. Third, high expression can be used to determine the specific cell type involved in cancers that have unknown origin and yet the gene is known (such as rhabdoid tumours and *SMARCB1*). In addition, beyond the basic task of linking genes to cancers, mimicking or generating the signals from these genes may ultimately provide methods of cancer prevention for the susceptible tissues.
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![**The results of the Kruskal--Wallis multiple comparison test are diagrammed for the *ATM* tumour suppressor gene for its initial test based on (A) tissue category and (B) the final test using the susceptible subtissue.** The figure shows the significance categories (A, AB, and so on) separating the samples. In the subtissue test, the susceptible tissue category (Immune System) was divided into a susceptible subtissue (lymph node) and a nonsusceptible subtissue (two subtissues) grouping (see [Table 1](#tbl1){ref-type="table"}).](bjc2015205f1){#fig1}

![**Expression levels (±1 s.e.) in susceptible tissues relative to nonsusceptible tissues for (A) TSGs and (B) POGs.** The 'Susceptible Subtissue/Tissue\' bars show the mean of log expression for the susceptible subtissue (where possible) or of the susceptible tissue. The 'Nonsusceptible Tissue\' bars show the average of the mean values for the nonsusceptible tissues. The letters above each 'Susceptible Subtissue/Tissue\' bar show its relevant significance category. The abbreviation for each gene is given on the x axis.](bjc2015205f2){#fig2}

###### The 12 broad tissue categories and the 38 subtissue types contained in the analysed multistudy data set that was compiled from 35 independent studies

  **Tissue category**                  **Sample size**     **Original data source**
  ----------------------------------- ----------------- -------------------------------
  **Adipocyte**                              14                      1, 2
   Adipose tissue normal                      8                         
   Adipose-derived adult stem cells           6                         
  **Bone**                                  **7**                      3
   Bone                                       7                         
  **Brain+nerve**                            150               4, 5, 6, 7, 8, 9
   Amygdala                                   1                         
   Brain                                     39                         
   Caudate nucleus                           30                         
   Cerebellum                                26                         
   Frontal cortex                            27                         
   Hippocampus CA1                            5                         
   Hypothalamus                              20                         
   Prefrontal cortex                          2                         
  **Endocrine organs**                        7                      7, 10
   Thyrocyte                                  6                         
   Thyroid gland                              1                         
  **Epithelium**                             33                       11
   Bronchial epithelium                      33                         
  **Gastrointestinal organs**                13                     12, 13
   Oesophagus epithelium                      7                         
   Small intestines                           6                         
  **Head+neck**                              33               14, 15, 16, 17, 18
   Conjuctiva                                 4                         
   Hypopharynx                                3                         
   Oropharynx                                 1                         
   T cell                                     9                         
   Tonsil                                    10                         
   Trabecular meshwork cell                   6                         
  **Heart+muscle**                           74          19, 20, 21, 22,23, 24, 25, 26
   Heart                                     36                         
   Myometrium                                12                         
   Skeletal muscle                           17                         
   Smooth muscle                              9                         
  **Immune system**                          25                   15, 27, 28
   CD34+ blood cell thymus                    1                         
   Lymph node                                10                         
   Thymocyte                                 14                         
  **Female reproductive**                    34                 26, 29, 30, 31
   Ovary                                      4                         
   Placenta basal plate                      21                         
   Smooth muscle                              1                         
   Theca                                      8                         
  **Male reproductive**                      12                     32, 33
   Prostate gland                            11                         
   Testis                                     1                         
  **Skin**                                   25                   26, 34, 35
   Endothelial cells                          8                         
   Epidermis                                  5                         
   Keratinocyte                               8                         
   Skin                                       4                         
  Total                                      427                        

The total number of biological samples being tested for each broad tissue category and its corresponding subtissues is shown. Each of the 35 independent studies are listed in numerical code next to the tissue categories for which they contributed data. See [Supplementary Table S1](#sup1){ref-type="supplementary-material"} for the complete reference corresponding to each code number. For additional details, see [@bib45]).

###### The susceptible tissue/subtissue and cancer type associated with the TSGs and POGs identified for analysis, plus the expression of these genes in susceptible *vs* nonsusceptible tissues

  **Gene type**             **Gene**    **High-penetrance cancer**        **Susceptible tissue type**    **Kruskal--Wallis test** ***P*****-value**  **Expression (susc. tissue)**   **Expression (other tissues)**    **Significance category**   **Relative expression**  **Susceptible subtissue**    **Rel. expr. in susc. subtissue**   **Subtissue significance category**
  ------------------------- ----------- --------------------------------- ----------------------------- -------------------------------------------- ------------------------------- -------------------------------- --------------------------- ------------------------- --------------------------- ----------------------------------- -------------------------------------
  Tumour suppressor genes   *ATM*       Leukaemia, lymphoma               Immune system                                   5.06E−15                   2.886±0.472                     −0.028±0.206                                A (2)                      7.54            Lymph node                                 11.68                                A (1)
                            *STK11*     gastrointestinal polyps           Gastrointestinal                                5.06E−15                   1.814±0.173                     0.108±0.224                                 A (2)                      3.26            Small intestine                            3.34                                 A (3)
                            *NF1*       Glioma, other CNS cancers         Brain and nerve                                 5.06E−15                   0.645±0.076                     −0.432±0.205                                A (1)                      2.11            NA                                                                                 
                            *RB1*       Osteosarcoma                      Bone                                            5.06E−15                   0.62±0.203                      −0.060±0.123                                A (2)                      1.60            NA                                                                                 
                            *SMAD4*     Gastrointestinal polyps           Gastrointestinal                                1.29E−03                   0.878±0.324                     0.260±0.106                                 A (2)                      1.53            Small intestine                            2.21                                 A (1)
                            *CDKN2A*    Melanoma                          Skin                                            2.99E−07                   0.904±0.510                     0.386±0.389                                   B                        1.43            Epidermis                                  0.41                                   E
                            *MEN1*      Parathyroid adenoma               Endocrine                                       5.06E−15                   −0.246±0.139                    −0.758±0.249                                  B                        1.43            Thyrocyte                                  1.26                                 A (7)
                            *BRCA2*     Prostate                          Male reproductive                               1.17E−10                   0.106±0.190                     −0.237±0.194                                 BC                        1.27            Prostate gland                             1.01                                 A (6)
                            *PRKAR1A*   Myxoma                            Heart and muscle                                5.06E−15                   0.655±0.099                     0.015±0.331                                  BC                        1.56            Heart                                      2.36                                 A (2)
                            *PHOX2B*    Neuroblastoma                     Brain and nerve                                 2.02E−12                   −0.066±0.067                    0.134±0.203                                  BC                        0.87            NA                                                                                 
                            *PTCH1*     Skin basal cell                   Skin                                            5.06E−15                   −0.069±0.116                    0.136±0.156                                  BC                        0.69            Keratinocyte                               0.86                                  BC
                            *MLH1*      Endometrial                       Female reproductive                             5.06E−15                   −0.211±0.088                    −0.387±0.190                                 CD                        1.13            Placenta basal plate                       1.19                                  CD
                            *BRCA1*     Ovarian                           Female reproductive                             5.06E−15                   −0.779±0.070                    −0.394±0.173                                 CDE                       0.77            Ovary                                      0.77                                  DE
                            *TP53*      Osteosarcoma                      Bone                                            5.06E−15                   −0.378±0.045                    −0.222±0.172                                  D                        0.90            NA                                                                                 
                            *MSH2*      Ovarian                           Female reproductive                             5.06E−15                   −0.807±0.081                    −0.487±0.157                                 DE                        0.80            Ovary                                      1.67                                 A (3)
                            *PRKAR1A*   Testicular                        Male reproductive                               5.06E−15                   −0.198±0.260                    0.093±0.335                                  EF                        0.82            NA                                                                                 
                                                                                                                        TSG average:                 0.368±0.254                     −0.130±0.082                                                                                                                                                              
  Proto-oncogenes           *RET*       Medullary thyroid                 Endocrine                                       1.40E−11                   7.097±2.437                     0.158±0.164                                 A (3)                     122.77           NA                                                                                 
                            *TSHR*      Thyroid adenoma                   Endocrine                                       7.13E−03                   6.588±4.292                     0.868±0.399                                 A (1)                      52.72           NA                                                                                 
                            *MPL*       Myeloproliferative disorder       Bone                                            1.08E−12                   2.594±0.598                     0.519±0.211                                 A (1)                      4.21            NA                                                                                 
                            *ALK*       Neuroblastoma                     Brain and nerve                                 5.06E−15                   0.697±0.065                     −0.261±0.108                                A (1)                      1.94            NA                                                                                 
                            *EGFR*      Non-small-cell lung cancer        Epithelium                                      5.06E−15                   0.473±0.056                     0.112±0.186                                 A (5)                      1.28            NA                                                                                 
                            *LMO1*      Neuroblastoma                     Brain and nerve                                 7.59E−07                   0.179±0.076                     0.106±0.140                                 ABCD                       1.05            NA                                                                                 
                            *KIT*       Gastrointestinal stromal tumour   Gastrointestinal                                5.06E−15                   1.053±0.255                     1.062±0.138                                  CD                        0.99            Small intestine                            0.79                                  CD
                            *HRAS*      Rhabdomyosarcoma                  Heart and muscle                                5.06E−15                   −0.743±0.089                    −0.76±0.329                                  DE                        1.01            Skeletal muscle                             1.6                                   C
                                                                                                                        POG average:                 2.24±1.06                       0.225±0.209                                                                                                                                                               

Abbreviations: CNS= central nervous system; NA=not applicable; POG=proto-oncogene; Rel. expr.=relative expression; susc.=susceptible; TSG=tumour suppressor gene.

For each gene, results are shown for the Kruskal--Wallis test across the 12 broad tissue categories (*P*-value=significance after Bonferroni correction) and the significance categories assigned to the susceptible tissue in the subsequent Kruskal--Wallis multiple comparison test. For genes in significance category 'A\', the total number of tissues tied in that category is given in parentheses. Also shown are the log~2~ expression (±1 s.e.) of each gene in the susceptible tissue type, the mean for the 11 other tissues and the ratio of these expression levels. For those genes that could also be analysed at the level of subtissue, the results from the subtissue analysis are also shown.

###### Variation in gene expression levels within and between laboratories testing the same subtissue

  **Tissue category**   **Subtissue**      **Lab ID**   **Sample size**   **Within-lab correlation (*****r***)   **Between-lab correlation (*****r***)
  --------------------- ----------------- ------------ ----------------- -------------------------------------- ---------------------------------------
  Brain+nerve           Caudate nucleus     E-AFMX-6          29                         0.715                                   0.732
                                            GSE3790            1                           NA                                       
  Heart+muscle          Heart               GSE2240           23                         0.722                                   0.880
                                             GSE974           13                         0.606                                      
  Heart+muscle          Smooth muscle      E-MEXP-569          8                         0.749                                   0.570
                                           E-MEXP-66           1                           NA                                       
  Endocrine organs      Thymocyte          E-MEXP-337         13                         0.623                                   0.853
                                            GSE1460            1                           NA                                       
  Brain+nerve           Brain               GSE5392           23                         0.582                                   0.662
                                            E-LGCL-5          15                         0.679                                   0.301
                                           E-TABM-145          1                           NA                                    0.598
  Heart+muscle          Skeletal muscle     GSE3307            9                         0.797                                   0.822
                                            GSE6011            7                         0.803                                   0.793
                                            GSE1786            1                           NA                                    0.449

  **Expression=subtissue+gene+lab(subtissue)+subtissue × gene+lab(subtissue) × gene**                           
  ------------------------------------------------------------------------------------- ------ -------- ------- ---------
  Subtissue                                                                               5     155.5    6.97     0.003
  Gene                                                                                    22    1003.7   11.86   \<0.001
  Lab(subtissue)                                                                          8      22.8     1.1     0.362
  Subtissue × gene                                                                       110    2510.6   6.14    \<0.001
  Lab(subtissue) × gene                                                                  176    554.2    4.18    \<0.001
  Error                                                                                  3303   2489.0               

The subtissues and their corresponding laboratories (represented by an ArrayExpress experiment ID) are given along with the number of tissue samples that were tested in each lab. For each lab (with sample size \>1) an average within-lab correlation was calculated using the expression values across all 23 genes in each sample. For each subtissue, the pairwise correlation between all labs is given (in the order lab 1 *vs* 2, 1 *vs* 3, and 2 *vs* 3) using the mean expression values across all 23 genes for each lab. The analysis of variance (ANOVA) model and results of the data analysis are shown at the bottom of the table.
